Dr. Michael Husak
Claim this profileMarshfield Clinic-Minocqua Center
Studies Cancer
Studies Bladder Cancer
14 reported clinical trials
31 drugs studied
Area of expertise
1Cancer
Stage IV
HER2 positive
Stage III
2Bladder Cancer
Stage IV
Affiliated Hospitals
Clinical Trials Michael Husak is currently running
Cemiplimab + Palbociclib
for Liposarcoma
This phase II trial compares the effect of treatment with palbociclib alone to treatment with palbociclib plus cemiplimab for treating patients with dedifferentiated liposarcoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Palbociclib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Cemiplimab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. The combination of these two drugs may be more effective in shrinking or stabilizing advanced dedifferentiated liposarcoma compared to palbociclib alone.
Recruiting1 award Phase 2
Pre- and Post-Surgery Chemotherapy
for Gallbladder Cancer
This phase II/III trial compares the effect of adding chemotherapy before and after surgery versus after surgery alone (usual treatment) in treating patients with stage II-III gallbladder cancer. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before surgery may make the tumor smaller; therefore, may reduce the extent of surgery. Additionally, it may make it easier for the surgeon to distinguish between normal and cancerous tissue. Giving chemotherapy after surgery may kill any remaining tumor cells. This study will determine whether giving chemotherapy before surgery increases the length of time before the cancer may return and whether it will increase a patient's life span compared to the usual approach.
Recruiting1 award Phase 2 & 315 criteria
More about Michael Husak
Clinical Trial Related1 year of experience running clinical trials · Led 14 trials as a Principal Investigator · 10 Active Clinical TrialsTreatments Michael Husak has experience with
- Gemcitabine Hydrochloride
- Cisplatin
- Paclitaxel
- Pembrolizumab
- Carboplatin
- Atezolizumab
Breakdown of trials Michael Husak has run
Cancer
Bladder Cancer
Squamous Cell Carcinoma
Small Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michael Husak specialize in?
Michael Husak focuses on Cancer and Bladder Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are HER2 positive.
Is Michael Husak currently recruiting for clinical trials?
Yes, Michael Husak is currently recruiting for 10 clinical trials in Minocqua Wisconsin. If you're interested in participating, you should apply.
Are there any treatments that Michael Husak has studied deeply?
Yes, Michael Husak has studied treatments such as Gemcitabine Hydrochloride, Cisplatin, Paclitaxel.
What is the best way to schedule an appointment with Michael Husak?
Apply for one of the trials that Michael Husak is conducting.
What is the office address of Michael Husak?
The office of Michael Husak is located at: Marshfield Clinic-Minocqua Center, Minocqua, Wisconsin 54548 United States. This is the address for their practice at the Marshfield Clinic-Minocqua Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.